Vertex Pharmaceuticals Inc / Ma last reported quarterly results on Nov 2, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $3.4 billion (+11.8% year over year) and diluted EPS of $2.56. It usually reports 33–43 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 33–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 2, 2026
33 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
3,441
+11.8%
|
654
-39.6%
|
2.56
-39.0%
|
|
Aug 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
3,334
+12.5%
|
1,100
+6.5%
|
4.31
+8.0%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2,987
+7.8%
|
1,031
+59.6%
|
4.02
+61.4%
|
|
Feb 12, 2026
43 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
3,190
+9.5%
|
1,191
+30.5%
|
4.65
+31.0%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3,076
+11.0%
|
1,083
+3.6%
|
4.20
+4.7%
|
|
Aug 4, 2025
35 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
2,965
+12.1%
|
1,033
+128.7%
|
3.99
+128.7%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2,770
+3.0%
|
646
-41.2%
|
2.49
-40.9%
|
|
Feb 10, 2025
41 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
2,912
+15.7%
|
913
-5.8%
|
3.55
-4.5%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 875320
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.